Why Are Steroids Avoided in Multifocal Motor Neuropathy?
At a Glance
Steroids are generally avoided in multifocal motor neuropathy because studies do not show meaningful benefit and some patients become weaker after treatment. IVIg is usually the first treatment, and nerve testing helps confirm the diagnosis before therapy is chosen.
If you have been diagnosed with Multifocal Motor Neuropathy (MMN), you may be wondering why corticosteroids like prednisone are not part of your treatment plan, especially since they are often used for other autoimmune diseases. The short answer is that steroids do not effectively treat MMN and can actually make muscle weakness worse in some people [1][2]. Instead, the usual first-line treatment for MMN is Intravenous Immunoglobulin (IVIg) [1][3].
(Important Safety Note: This information is about using steroids to treat MMN. If you are already taking steroids for another medical condition, do not stop taking them abruptly. Always discuss any medication changes with your prescribing doctor, as suddenly stopping steroids can be dangerous.)
Why MMN is Different from Other Neuropathies
It is common to confuse MMN with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Both are nerve disorders involving the immune system, but they attack the nerves differently.
In CIDP, the immune system primarily attacks the myelin sheath—the protective covering around the nerves [4][5]. Typical CIDP often responds well to the broad anti-inflammatory effects of corticosteroids [6].
In contrast, current research suggests that MMN involves an immune attack directed at the nodes of Ranvier (small gaps in the myelin sheath) and the underlying motor nerve fibers (axons) [4]. This localized attack often involves different immune pathways, and sometimes specific antibodies called anti-GM1 antibodies are present [1]. Because the underlying disease process is different, the broad immune suppression provided by steroids does not effectively stop the nerve damage in MMN [6].
The Risks of Steroids in MMN
Neurologists advise against using corticosteroids as a treatment for MMN for two main reasons:
- Lack of Benefit: Studies consistently show that steroids do not improve the symptoms of MMN [1][3].
- Potential to Worsen Symptoms: More concerningly, some patients experience an active worsening of their muscle weakness when treated with steroids [2][7]. While the exact biological reason for this is not entirely understood, it is a known risk.
Using steroids also exposes patients to side effects without offering any benefit for their MMN [6]. (If you experience sudden or rapidly progressing weakness, or new trouble breathing or swallowing, seek urgent medical help. Do not automatically attribute these symptoms to MMN or a medication reaction without an evaluation.)
Treatment Alternatives
Because MMN does not respond to steroids, the main treatment is Intravenous Immunoglobulin (IVIg), which is an infusion of healthy antibodies given through a vein. IVIg is generally the first-line treatment and helps many people improve their muscle strength and stabilize their condition [1][6]. However, the response varies from person to person. IVIg is not a cure, and it may not reverse weakness caused by long-standing nerve damage.
Treatment often requires ongoing infusions. Once a patient’s condition is stabilized, they may sometimes transition to subcutaneous immunoglobulin (SCIg)—a similar treatment given as an injection under the skin—for long-term maintenance therapy [8].
The Importance of an Accurate Diagnosis
Because MMN is rare, ensuring an accurate diagnosis is critical. MMN typically causes uneven (asymmetric) muscle weakness without numbness or sensory loss [1][5]. Neurologists use nerve conduction studies (tests that measure how electrical signals travel through your nerves) to look for specific patterns of nerve block [1][5].
Doctors may also test your blood for anti-GM1 antibodies. While these antibodies support an MMN diagnosis, they are only found in about half of patients. A negative test result does not mean you don’t have MMN [1].
(Note: There is a rare subtype of CIDP called “motor CIDP” that can look clinically very similar to MMN. Motor CIDP can sometimes respond to steroids, but patients can also worsen, making the distinction very challenging [9]. This is why working with a neuromuscular specialist to confirm your diagnosis is so important.)
Common questions in this guide
Why don’t steroids usually help multifocal motor neuropathy?
Can steroids make muscle weakness from MMN worse?
What is used to treat MMN instead of steroids?
How do doctors distinguish MMN from motor CIDP?
Does a negative anti-GM1 antibody test rule out MMN?
What should I do if I need steroids for another illness?
Related questions
Show more
Get notified when new evidence is published on Multifocal motor neuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
[Multifocal Motor Neuropathy].
Kanda S, Kanda T
Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(5)):526-533 doi:10.11477/mf.1416202639.
PMID: 38741492 - 2
MULTIFOCAL MOTOR NEUROPATHY: CASE REPORTS.
Jusufović E, Sinanović O, Zukić S, et al.
Acta clinica Croatica 2018; (57(3)):581-587 doi:10.20471/acc.2018.57.03.23.
PMID: 31168193 - 3
Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.
Nobile-Orazio E, Gallia F, Terenghi F, Bianco M
Expert review of neurotherapeutics 2017; (17(8)):755-765 doi:10.1080/14737175.2017.1340832.
PMID: 28597710 - 4
Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Dyck PJ, Taylor BV, Davies JL, et al.
Muscle & nerve 2015; (52(4)):488-97 doi:10.1002/mus.24707.
PMID: 25976871 - 5
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Dyck PJB, Tracy JA
Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.
PMID: 29866282 - 6
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.
European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.
PMID: 34327760 - 7
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition.
Adreana Kleinveld VE, Wanschitz J, Löscher WN, et al.
Immunotherapy 2024; (16(9)):597-601 doi:10.1080/1750743X.2024.2342238.
PMID: 39052281 - 8
Switch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study.
Gingele S, Saparilla Pietschmann AC, Jendretzky KF, et al.
Neurology and therapy 2026; (15(1)):165-177 doi:10.1007/s40120-025-00848-1.
PMID: 41254424 - 9
Treatment Approaches for Atypical CIDP.
Menon D, Katzberg HD, Bril V
Frontiers in neurology 2021; (12()):653734 doi:10.3389/fneur.2021.653734.
PMID: 33790853
This page is for informational purposes only and does not constitute medical advice about MMN or steroid use. Do not start steroids, stop them abruptly, or change IVIg without speaking with your prescribing clinician.